In Vitro Intrinsic Clearance-Based Optimization ofN3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists
Citations Over Time
Abstract
A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF(1) receptor antagonists wherein sites of metabolism were identified by incubation with human liver microsomes. It was found that the rate of metabolism could be decreased by incorporation of appropriate substituents at the primary sites of metabolism. This led to the discovery of compound 12x, a highly potent (IC(50) = 1.0 nM) and selective CRF(1) receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.
Related Papers
- → Oral bioavailability of 17β-estradiol and various ester prodrugs in the rat(1991)16 cited
- → Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats(2015)28 cited
- → Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data(1982)18 cited
- → Bioavailabilities of omeprazole administered to rats through various routes(1995)4 cited
- → Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination(1981)69 cited